Table 3. Ongoing immunotherapy trials for patients with TETs.

Intervention	Tumor type	Clinical trial ID	Primary objective
Avelumab	Thymic carcinoma, Thymoma	NCT03076554	Safety and response rate
Nivolumab	Thymic carcinoma, B3 thymoma	NCT03134118	Six-month PFS
Pembrolizumab	Thymic carcinoma, Thymoma	NCT03295227	Dose limiting toxicity
Pembrolizumab and Sunitinib	Thymic carcinoma	NCT03463460	Response rate
Pembrolizumab and Epacadostat	Thymic carcinoma	NCT02364076	Response rate

TET, thymic epithelial tumor; PFS, progression-free survival.